LOKELMATM Sodium Zirconium Cyclosilicate

SWIFT* K+ REDUCTION AFTER ONE HOUR.1,2
SUSTAINED K+ CONTROL FOR UP TO ONE YEAR
WHEN USED AS A MAINTENANCE THERAPY.†1
NOW IN YOUR HANDS.
New, highly-selective LOKELMA (sodium zirconium cyclosilicate)
is indicated for the treatment of hyperkalaemia in adult patients1

*In an emergency situation, standard of care should be used in line with local or national guidelines
Clinical trials with LOKELMA have not included exposure longer than one year

Clinical Studies

HARMONIZE Across Patient Types

Consistent K+ response across patient types2

LOKELMA consistently reduced serum K+, regardless of comorbidities*, baseline K+ level or use of RAASi therapy2

The maintenance studies included patients with chronic kidney disease (58%), heart failure (10%), diabetes mellitus (62%) and RAASi therapy (68%)1

*CKD history, CKD eGFR, heart failure, diabetes mellitus, taking RAASi.

Mean serum K+ levels at 0 and 48 hours across baseline K+ levels.2

Mean serum K+ levels at 0 and 38 hours across baseline K+ levels
Mean serum K+ levels at 0 and 38 hours across baseline K+ levels

Adapted from Kosiborod M, et al. JAMA. 2014;312(21):2223-2233.2